A Study of Second-line Treatment With Apatinib After TACE in Advanced Hepatocellular Carcinoma Patients
Status:
Unknown status
Trial end date:
2019-03-01
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the efficacy and safety of TACE combined with apatinib in
treating advanced hepatocellular carcinoma. The primary endpoint is progression-free survival
(PFS), 3-month PFS, 6-month PFS and 1-year PFS.